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Objectives: We describe treatment failure rates by antibiotic duration for prosthetic joint infection (PJI)
managed with debridement, antibiotics and implant retention (DAIR).
Methods: We retrospectively collected data from all the cases of PJI that were managed with DAIR over
a 5 year period. Surgical debridement, microbiological sampling, early intravenous antibiotics and pro-
longed oral follow-on antibiotics were used.
Results: One hundred and twelve cases of PJI were identiﬁed. Twenty infections (18%) recurred during
a mean follow-up of 2.3 years. The mean duration of antibiotic use was 1.5 years. Failure was more
common after arthroscopic debridement, for previously revised joints and for Staphylococcus aureus
infection. There were 12 failures after stopping antibiotics and 8 while on antibiotics [hazard ratio
(HR)54.3, 95% conﬁdence interval (CI) 1.4–12.8, P50.01]. However, during the ﬁrst 3 months of
follow-up, there were eight failures after stopping antibiotics and two while on antibiotics (HR57.0,
95% CI 1.5–33, P50.015). The duration of antibiotic therapy prior to stopping did not predict outcome.
Conclusions: PJI may be managed by DAIR. The risk of failure with this strategy rises after stopping
oral antibiotics, but lengthening antibiotic therapy may simply postpone, rather than prevent, failure.
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Introduction
Arthroplasty is one of the most cost-effective healthcare inter-
ventions described,
1–3 but prosthetic joint infection (PJI) pre-
sents a major challenge to patients, physicians and funding
agencies. PJI complicates up to 2.5%
4 of the estimated 600000
primary arthroplasties
5 performed annually in the USA.
Established PJI usually proves intractable to antibiotics alone,
which led to the development of one- or two-stage surgical
exchange revision protocols to achieve satisfactory outcomes.
6
Two-stage exchange, requiring two surgical procedures as a
minimum, may present the patient and surgeon with signiﬁcant
attendant surgical and peri-operative risk including a substantial
period of reduced mobility. Removal of a soundly ﬁxed prosthe-
sis with any bone cement may also result in degradation of the
bone stock and peri-operative fracture. This makes the approach
of debridement, antibiotics and implant retention (DAIR) attrac-
tive, especially in the elderly or inﬁrm.
7 There is evidence, in
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8,9 and human
10–16 studies, that combinations of a ﬂuoro-
quinolone and rifampicin are effective treatments in
device-related staphylococcal infections.
Variable success rates (14%–100%) are reported for
DAIR
10–36 with a range of factors identiﬁed as conferring a
poor prognosis including delay to debridement, age of implant,
presence of a sinus, implant loosening, arthroscopy and
Staphylococcus aureus. Other factors, including the choice and
duration of both intravenous (iv) and oral antibiotics, are less
well deﬁned. In this study, we report the outcome in 112 patients
managed with DAIR. We analysed these data to describe the
impact of the length of oral antibiotic use on failure rates.
Methods
This was a retrospective series of all cases of PJI managed with our
DAIR protocol in the Bone Infection Unit of the Nufﬁeld
Orthopaedic Centre, Oxford, UK, between 1 January 1998 and 30
April 2003. Cases were managed by infectious disease physicians
and orthopaedic surgeons in a multi-disciplinary team. We estab-
lished a registry and included all cases of PJI using multiple data
sources: histopathology and outpatient parenteral antimicrobial
therapy (OPAT) databases; hospital activity coding databases; sys-
tematically hand-searched diagnostic details listed in outpatient
clinic letters; and prospective capture of patients attending follow-up
outpatient appointments or readmitted to our unit. The use of mul-
tiple data sources appeared to result in the capture of all cases
during this period, since all cases were represented in at least two
data sources.
Following a review of the case notes of all patients in the regis-
try, we excluded patients whose primary management of infection
was revision surgery or suppressive antibiotic therapy without debri-
dement, or whose only debridement and retention procedure was
carried out at a referring hospital.
A single dedicated researcher (S. M.) extracted data from case
notes of included patients for entry into a Microsoft Access data-
base. The senior investigators (I. B., B. L. A. and A. B.) each vali-
dated data from a different random set of these case notes (totalling
10% of the case notes) by independent extraction of the dataset and
reconciliation of the two extractions. Differences were resolved by
group discussion (S. M., A. B., B. L. A. and I. B.) and all afﬁrmed
the accuracy of the data extracted by the primary data abstractor
(S. M.). Differences in data were resolved and the data locked
before any preliminary analysis took place, but researchers were not
blinded to outcomes.
Case deﬁnition
Cases were deﬁned as those having a clinical syndrome of arthro-
plasty infection triggering the DAIR protocol (any of persistent
wound inﬂammation, wound discharge or intra-operative purulence
in the context of a soundly ﬁxed implant) and at least one culture-
positive deep peri-prosthetic sample and/or histology of peri-
prosthetic tissues indicative of infection. Patients with clinical or
radiographic evidence of joint loosening were not managed with
DAIR; for them, staged revision was the standard of care. Patients
were not excluded based on their previous history of joint infection
or on the duration of their symptoms. Multiple samples were taken
for microbiological culture as described previously.
37 The histologi-
cal diagnosis was made on the basis of the degree of inﬁltration by
neutrophil polymorphonuclear leucocytes as outlined in previous
studies.
38,39
Deﬁnition of treatment failure
We deﬁned treatment failure as: (i) infection recurrence with posi-
tive cultures from peri-prosthetic samples or an aspirate; (ii) wound
or sinus drainage recurring or persisting for 3 months beyond the
index debridement procedure; or (iii) a requirement for revision
surgery (irrespective of the indication). Repeated debridements were
not considered treatment failure, and the monitoring period for treat-
ment failure began after the last debridement of the acute episode.
Data collection
We collected data from the patient notes on patient demographics,
co-morbidities (diabetes, renal failure, immunosuppression, rheuma-
toid arthritis, malignancy and smoking), the dates of primary
surgery, symptom onset, presentation and debridement; clinical fea-
tures at presentation and surgical ﬁndings; nature of implant;
number of debridements; microbiology; antibiotic choice, duration
and side effects; and outcomes. We categorized infections by organ-
ism, and by age of implant rather than exogenous versus haema-
togenous, since these ﬁrst two variables were directly observed and
known in all cases, and less open to interpretation. The data were
then anonymized. There was no research-related contact with
patients, and informed consent was not required. All activity was
conducted in accordance with the Declaration of Helsinki and
national and institutional standards.
Clinical management
During the period of retrospective study, protocols guiding operative
sampling, deﬁnitions of infection and antibiotic use were used by
the multi-disciplinary clinical teams involved in patient care, and
overseen by the infection physician.
Antibiotic management
Empirical antibiotics were avoided prior to DAIR. If antibiotics had
been initiated elsewhere, surgery was delayed, if clinically safe, to
achieve a minimum 48 h antibiotic-free interval prior to microbiolo-
gical sampling. Following intra-operative sampling, whilst debride-
ment continued, patients received empirical iv vancomycin 1 g
(continued as 1 g initially 12 hourly) plus meropenem 500 mg (con-
tinued as 500 mg 8 hourly).
40 Therapy was rationalized once deﬁni-
tive culture results were obtained from the laboratory. Meropenem
was discontinued at 48 h if no aerobic Gram-negative pathogens
requiring treatment with a carbapenem had been cultured.
Intravenous antibiotic therapy was continued for 6 weeks with a
b-lactam or glycopeptide, since organisms may more readily acquire
resistance to our preferred oral regimens (rifampicin and quino-
lones). The risk of this is greatest at the start of therapy when there
is a high bioburden. If patients were suitable for OPAT, the pre-
ferred treatment was with ceftriaxone (1 g daily) for most suscep-
tible pathogens or with teicoplanin (400 mg daily following loading,
adjusted by levels) for coagulase-negative staphylococci and
methicillin-resistant Gram-positive organisms. Patients with negative
cultures were treated with glycopeptides.
41 We treated Gram-
negative organisms that were resistant to cephalosporins or associ-
ated with inducible resistance to cephalosporins with a carbapenem.
Patients with side effects were switched to alternative agents where
possible. For staphylococci, we preferred oral follow-on with a
ﬂuoroquinolone/rifampicin combination (typically ciproﬂoxacin
500 mg twice daily plus rifampicin 300 mg twice daily). If the
organism was resistant, or the drugs poorly tolerated, we used
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or amoxicillin for oral follow-on therapy. If the susceptibility pro-
ﬁles permitted, we used single oral agents for streptococci and
Gram-negative organisms. For polymicrobial infections, antibiotic
regimens with activity against all cultured pathogens were used. The
duration of oral therapy was speciﬁed to patients and primary care
physicians as a minimum of 12 months. However, because of the
uncertainty on optimal duration, treatment decisions were made case
by case, considering drug side effects, the potential risks of revision
surgery in the event of failure, quality of life and patient preference.
This resulted in a range of durations used in our clinical practice.
Surgical management
The surgical strategy for DAIR commenced with excision of the
wound margins followed by removal of necrotic soft tissue, debris,
haematoma or collections of pus from around the prosthesis.
Intra-operative samples were taken at arthrotomy from multiple
samples of tissue, haematoma and pus from the vicinity of the pros-
thesis for culture and histology. Each sample was obtained with sep-
arate instruments and placed into separate containers for processing
as described previously.
37 The prosthesis was assessed for integrity
of the cement–bone or prosthesis–bone interfaces and if ﬁrmly
ﬁxed and mechanically sound it was retained. Any modular prosthe-
sis components were exchanged when an open debridement was
performed, and any loose bone graft was removed. The exposed
tissue surfaces were irrigated with aqueous chlorhexidine using
pulsed lavage. Wounds were always closed primarily over drains,
which were removed at 48 h or when drainage ceased. For knee and
ankle replacements, arthroscopic washout was sometimes used with
sampling of ﬂuid and tissue carried out via multiple portals followed
by high-ﬂow irrigation.
Analysis
We used STATA version 10 (Stata Corp., College Station, TX, USA) to
run Cox survival analyses. Data were censored from follow-up after
recurrence of infection or when lost to follow-up. The endpoint for
treatment failure was as deﬁned above. Univariate analysis was con-
ducted on factors relevant to presentation or initial treatment and, sub-
sequently, multivariate analysis was conducted on factors that were
signiﬁcant or of borderline signiﬁcance (P,0.1) on univariate analysis.
We compared the risk of treatment failure on oral antibiotics with
the risk off antibiotics. To do this, we analysed the failure rates of
subjects taking oral antibiotics, on stopping antibiotics and (as a
control for the effect of time elapsed) at day 500 after debridement
without reference to antibiotic therapy. We used the robust cluster
estimator to adjust P values and conﬁdence intervals (CIs) to account
for this.
42 These analyses were adjusted for the factors found to
predict failure signiﬁcantly on multivariate analysis. In these ana-
lyses, we included the ﬁrst 250 days only, so as to ensure comparable
levels of follow-up in patients stopping antibiotics. A test of pro-
portional hazards using Schoenfeld’s residuals was used to examine
for a signiﬁcant change in hazard ratios (HRs) over time.
43
Results
Characteristics of the cohort
One hundred and twelve cases of PJI (52 hips, 51 knees and 9 other
total joint replacements) were identiﬁed. Nearly half of the patients
treated with the DAIR protocol were 70 years of age or older
(Table 1). There was a high incidence of co-morbidity, with more
than half the patients having at least one co-morbid condition.
Sixty-nine percent had arthroplasties that were ,90 days old,
and 63% were treated surgically within 3 days of presentation.
S. aureus was frequently isolated from surgical specimens (42%),
but methicillin-resistant S. aureus (MRSA) was rare (8%).
Eighty-seven percent of the patients were treated with an
open debridement and 13% with an arthroscopic washout. Some
patients required multiple procedures (21%).
We observed 20 treatment failures (18%) during a mean
follow-up of 2.3 years (Figure 1); 89%, 81% and 78% of joints
had not failed at 1, 2 and 3 years, respectively.
The mean subsequent duration of oral antibiotic use was
1.5 years. Eighty-four percent received rifampicin, 59% cipro-
ﬂoxacin and 59% received both. Tetracyclines (20%), b-lactams
(13%), fusidic acid (6%) and clindamycin (4%) were also used.
Among patients with staphylococcal disease, 94% received
rifampicin, 70% ciproﬂoxacin and 70% both. Twenty-three
percent of the patients received ,4 weeks of iv antibiotics. For
91% of these shortened courses, a side effect was responsible.
These were a rash (40%), diarrhoea (26%), nausea (10%), hepa-
titis (10%) and presumed drug fever (10%).
S. aureus, previous revision and arthroscopic washouts
predicted treatment failure
We used univariate analysis (Table 1) to select factors for a
multivariate model (Table 2). Both MRSA and methicillin-
susceptible S. aureus infection were individually associated with
non-signiﬁcant increases in the risk of treatment failure, but the
combined group with S. aureus infection had an increased risk
of treatment failure of borderline signiﬁcance, which was
included in the multivariate model (HR¼2.9, 95% CI 1.0–8.4,
P¼0.05; Figure 2a). Only three patients (3%) were culture-
negative. Previously revised joints were associated with a
signiﬁcant risk of treatment failure (HR¼3.1, 95% CI¼1.2–
8.3, P¼0.008; Figure 2b), as were joints treated with arthro-
scopic washouts (HR¼4.2, 95% CI 1.5–12.5, P¼0.008;
Figure 2c).
Joint replacements presenting at 90 days or longer post-
implantation were associated with treatment failure on univariate
analysis, but not on multivariate analysis (HR¼1.1, 95% CI
0.31–3.8, P¼0.89). Arthroscopic washouts were more often
performed in arthroplasties that were  90 days old, and once
arthroscopic washout was included as a factor, age of implant
did not inﬂuence outcome. The effect of an arthroscopic
washout was signiﬁcant even when analysis was restricted to
joint replacements ,90 days old (HR¼18, 95% CI 1.7–200,
P¼0.018). We used 90 days to classify on the basis of time to
presentation based on previous literature,
36 but similar results
were obtained using the alternative 30 day cut-off.
44 Hip infec-
tion appeared to be associated with a reduced risk of recurrent
infection on univariate analysis, but this effect was no longer
apparent after adjusting for the effect of arthroscopic washouts,
which are only done for knees (adjusted HR¼0.9, 95% CI
0.29–2.8, P¼0.8).
An iv antibiotic course lasting  28 days was associated with
halving the risk of treatment failure, which was of borderline
statistical signiﬁcance in a univariate model (Figure 2d), but was
not signiﬁcant in the multivariate model. An iv antibiotic course
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1266Table 1. HRs from survival analysis (Cox regression) for the association of individual factors with failure
Variable/category n Number failing Hazard ratio 95% CI P
Gender
female 50 10 1
male 62 10 0.7 0.30–1.73 0.47
Age (years)
,40 2 0 —
40–49 2 1 —
50–59 22 4 1
60–69 34 5 0.8 0.21–3 0.75
70–79 35 7 1.2 0.35–4.1 0.86
80–89 17 3 1.1 0.26–5.13 0.92
Co-morbidity
none 45 4 1
one or more 66 15 2.7 0.91–8.3 0.07
unknown 1 1
Time from implant to debridement (days)
,90 77 9 1
 90 35 11 3.0 1.2–7.2 0.016
Time from presentation to debridement (days)
,37 1 9 1
3–14 25 6 0.77 0.24–2.5 0.67
.14 16 5 0.36 0.12–1.0 0.07
Arthroplasty
primary implant 86 11 1
revised implant 26 9 2.6 1.1–6.3 0.031
Surgical debridement
open debridement 97 12 1
arthroscopy 15 8 5.4 2.2–13 ,0.0005
Joint
hip 52 7 1
knee 51 13 0.47 0.19–1.18 0.10
ankle 3 0 —
shoulder 2 0 —
elbow 4 0 —
Surgical ﬁndings
no pus at surgery 54 8 1
pus at surgery 48 1 1.5 0.59–3.65 0.41
unknown 10 11 —
Number of debridements
single procedure 88 14 1
multiple procedures 24 6 1.8 0.68–4.7 0.24
Microbiology
a
MRSA 9 3 2.0 0.59–7 0.26
MSSA 39 10 1.8 0.71–4.4 0.21
CoNS 26 5 1.0 0.36–2.8 0.99
S. aureus 47 13 2.6 0.97–6.9 0.052
Intravenous antibiotics
,28 days 26 8 1
 28 days 86 12 0.41 0.16–0.99 0.050
MRSA, methicillin-resistant S. aureus; MSSA, methicillin-susceptible S. aureus; CoNS, coagulase-negative staphylococci.
aMultiple organisms can be isolated from one patient, hence the sum of n is .112.
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worse outcome (HR¼1.3, 95% CI 0.5–3.3), but is strongly con-
founded since a duration longer than speciﬁed by the protocol
was only used where oral therapy was not possible, or where
repeated debridements were undertaken.
There was a trend towards better outcomes in patients with a
longer time between presentation and debridement (Table 1) on
univariate analysis. However, the signiﬁcance was marginal and
we had no data on the reasons for delay to debridement, and so
did not include this variable in further models because of the
potential for bias (i.e. that a delay was more likely with less
severe disease).
The risk of treatment failure rises after stopping antibiotics
We examined two rates of failure; those seen in all patients
treated with the DAIR protocol, and those seen after oral anti-
biotics were stopped (resetting the day of stopping oral anti-
biotics to day 0 to plot a new survival curve). The risk of
treatment failure increased more than 4-fold after stopping oral
antibiotics (Figure 3). The majority of the recorded failures were
during the ﬁrst 4 months after stopping antibiotics. A test of
Schoenfeld’s residuals for changing proportional hazards
43 was
positive (P¼0.015), indicating a signiﬁcant change in the rela-
tive risk of failure over time. The 4-fold rise in hazard on stop-
ping antibiotics therefore represents an early period of high risk
and a later period of lower risk. An HR estimated over only the
ﬁrst 3 months was 7.0 (95% CI 1.5–33, P¼0.015) and the HR
over the next 3 months was 1.4 (95% CI 0.1–19, P¼0.79).
There was no trend of lower failure rates with longer antibiotic
use (Figure 4).
Length of follow-up does not explain the increased risk of
failure on stopping antibiotics
We reasoned that the increased risk of failure on stopping anti-
biotics might be due to the greater time that had elapsed since
DAIR was undertaken. To explore this possibility, we examined
the rate of failure in all patients who were still under follow-up
after 500 days (resetting day 500 as day 0). The risk of failure in
the cohort still under follow-up from day 500 was similar to the
risk from day 0 (HR¼1.4, 95% CI 0.5–3.9, P¼0.47),
suggesting that the increased rates of failure seen on stopping
antibiotics were not confounded by the greater time that had
elapsed since DAIR.
Discussion
This is the largest study to date that describes the antibiotic and
surgical treatments of infected arthroplasties with DAIR.
18 We
achieved successful salvage of the infected arthroplasty at 1, 2
and 3 years of 89%, 81% and 78%, respectively. It is difﬁcult to
compare these outcomes with those obtained elsewhere without
data on the subgroups of patients selected for DAIR rather than
other treatment strategies.
However, we do clearly show that the rate of failure
increased 4-fold after stopping antibiotics. Despite the
increased risk of the recurrence of infection, this only affected
a minority of patients stopping antibiotics. This suggests that
the combination of debridement and prolonged antibiotics
results in a cure of infection for many patients, but a suppres-
sion of infection in a subgroup who then relapse once anti-
biotics are stopped. The length of antibiotic prescribing before
stopping antibiotics did not appear to alter the outcome, and
most failures occurred in the ﬁrst 4 months after stopping anti-
biotics (despite a median follow-up time of a year after stop-
ping). The resulting change in the HR over time was
signiﬁcant (P¼0.015). This predicts that the survival plots in
Figure 3 will eventually meet, but there was insufﬁcient data
to test this. One might conclude that most patients cured of
PJI by DAIR are cured early on, and that prolonged antibiotic
therapy does not prevent treatment failures in those who are
not cured, but merely postpones them. However, there were
few patients receiving ,6 months of antibiotic treatment, so
these data cannot be used to support shortening oral antibiotic
courses below 6 months. Life-long antibiotics might simply
postpone, rather than prevent, treatment failure, but this may
be all that is required for older patients with limited life
expectancy. For patients in whom further surgery might be
limb- or life-threatening, postponing this outcome with indeﬁ-
nite antibiotic treatment is also justiﬁed.
Although we adjusted for a number of factors besides anti-
biotic use that might inﬂuence outcome, we cannot exclude con-
founding from unmeasured factors including radiographic status,
functional status and inﬂammatory markers. It is possible that
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Figure 1. Kaplan–Meier plot of time to treatment failure for all patients,
showing all follow-up data available.
Table 2. Multiple Cox regression model of signiﬁcant factors from
univariate analysis
Hazard ratio 95% CI P
Implant to debridement  90 days 1.1 0.31–3.8 0.89
Intravenous antibiotics  28 days 0.49 0.18–1.37 0.18
Arthroscopy versus open 4.2 1.5–12.5 0.008
S. aureus 2.9 1.0–8.4 0.050
Revised versus primary arthroplasty 3.1 1.2–8.3 0.008
Presence of co-morbidity 1.81 0.55–5.9 0.32
Goodness of ﬁt: log likelihood¼259.6, x
2¼17.2, P¼0.0006.
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1268patients with a poorer prognosis used longer courses of anti-
biotics, and failure rates might have increased had the course
been reduced in length. However, such a bias would be expected
to result in patients with a better prognosis stopping antibiotics,
and hence lower apparent failure rates after stopping. In fact, we
observed the opposite (i.e. an increased failure rate after
stopping).
We found that outcomes were worse when attempting to
salvage a revision implant, when an arthroscopic washout was
used or when S. aureus infection was identiﬁed. The poorer
bone stock, abnormal soft tissue and meshes or bone grafts
associated with revision implants may lead to poorer outcomes.
Arthroscopy results in a less thorough debridement and pre-
cludes exchanging modular components. However, these results
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Figure 2. Kaplan–Meier plots for time to failure are shown for (a) the presence or absence of S. aureus infection, (b) primary versus previously revised
implant, (c) arthroscopic versus open debridement and (d) length of intravenous (iv) antibiotic use. The x-axes show days since DAIR and the y-axes show
the proportion without treatment failure. The numbers at risk at each timepoint are shown beneath each plot.
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Figure 4. Kaplan–Meier plot of time to treatment failure for patients at the
start of the DAIR protocol and patients stopping oral antibiotics (where day
of stopping is day 0), divided according to the length of use of oral
antibiotics prior to stopping: ,180 days oral suppression, HR¼3.7 (95% CI
0.7–18), P¼0.11; 181–360 days oral suppression, HR¼9.1 (95% CI 0.9–
90), P¼0.058; and .360 days oral suppression, HR¼5.1 (95% CI 1.4–19),
P¼0.013.
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Figure 3. Kaplan–Meier plot of time to treatment failure for patients on
oral antibiotics (HR¼1) and patients stopping oral antibiotics (where day of
stopping is day 0, HR¼4.3, 95% CI 1.4–12.8, P¼0.01).
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tional study design. We do not know why arthroscopy was
selected for a small subset of patients, and the result might be
confounded, for instance by co-morbidity leading to both poorer
outcomes and a decision to undertake a less invasive procedure.
However, there was no evidence that afﬁrmed co-morbidity was
associated with either revision implants (P¼0.87) or arthro-
scopy (P¼0.67). The published literature gives conﬂicting
results regarding the efﬁcacy of arthroscopic washout in earlier,
smaller studies,
15,31,32,35 and S. aureus infection has previously
been identiﬁed as an adverse factor, despite various antibiotic
regimens.
25,26
Our data were equivocal regarding the effect of the age of
the implant (which would have indicated immediate revision in
some protocols). Although in univariate analysis, older implants
appeared more likely to fail following DAIR, this was not seen
in multivariate analysis. Older implants were more likely to be
treated with arthroscopic washout (for technical reasons, this is
less often performed after recent implantation). Arthroscopic
washout was the stronger factor in multivariate analysis and was
still signiﬁcant after restricting analysis to recent implants.
Previous studies have shown a worse outcome for older
implants
15,19 and where debridement is delayed.
14,24 However,
these differences may simply reﬂect differences in patient selec-
tion and local practice, since in all these studies (ours included),
there is limited data on the factors inﬂuencing patient selection.
In summary, we present the largest study to date on outcomes
after DAIR for infected joint prostheses. These data suggest that
the length of duration of antibiotic prescribing beyond 6 months
is not critical to the outcome, but that patients should be warned
of an increase in the risk of treatment failure, particularly during
the ﬁrst 3 or 4 months after stopping antibiotics. These con-
clusions should now be tested in prospective randomized con-
trolled trials of prolonged versus shortened antibiotic treatment.
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